More than 90% of drugs that work in animal models fail in human clinical trials. That is not a rounding error. It is a breakdown in the basic information architecture of preclinical development. Investors rationally discount preclinical data because the data is, frankly, not very good. But the clinical data that would convince them costs $10-50M to generate. Early-stage companies need money to produce the signals that would qualify them to raise money. That is the paradox.

This report profiles 79 companies across 8 categories that are attacking this problem from every angle: organs-on-chips that generate data in human tissue instead of mice, organoid platforms that preserve patient-level tumor heterogeneity, digital twin engines that simulate clinical outcomes before the first human dose, and automated screening platforms that collapse the cost of generating a meaningful preclinical signal by an order of magnitude.

The regulatory tailwind is real. In 2025, the FDA began phasing out mandatory animal testing for monoclonal antibodies, and the NIH stopped funding animal-only grant proposals. The companies in this report are not building into uncertainty. They are building into structural demand.